Pictet Asset Management Holding SA lifted its position in Alumis Inc. (NASDAQ:ALMS – Free Report) by 6,070.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 647,366 shares of the company’s stock after buying an additional 636,875 shares during the period. Pictet Asset Management Holding SA’s holdings in Alumis were worth $4,784,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in ALMS. Integrated Wealth Concepts LLC purchased a new stake in shares of Alumis during the second quarter valued at approximately $33,000. KBC Group NV bought a new position in Alumis in the 1st quarter valued at approximately $42,000. State of Wyoming bought a new position in Alumis in the 1st quarter valued at approximately $57,000. EverSource Wealth Advisors LLC lifted its position in Alumis by 600.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock valued at $69,000 after acquiring an additional 2,684 shares in the last quarter. Finally, Assetmark Inc. purchased a new stake in Alumis during the 1st quarter valued at $92,000.
Wall Street Analysts Forecast Growth
A number of analysts have commented on ALMS shares. Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Robert W. Baird set a $27.00 price target on Alumis in a report on Tuesday, September 1st. Weiss Ratings downgraded Alumis from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 27th. Morgan Stanley dropped their price objective on Alumis from $39.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. Finally, Oppenheimer reduced their price objective on Alumis from $55.00 to $37.00 and set an “outperform” rating for the company in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.09.
Get Our Latest Research Report on Alumis
Alumis Price Performance
Alumis stock traded down $0.53 during midday trading on Friday, reaching $5.60. 1,492,040 shares of the company traded hands, compared to its average volume of 1,844,219. The firm has a market capitalization of $724.81 million, a price-to-earnings ratio of -1.59 and a beta of -0.28. The business has a 50 day moving average of $7.24 and a two-hundred day moving average of $20.46. Alumis Inc. has a 12 month low of $4.60 and a 12 month high of $31.35.
Alumis (NASDAQ:ALMS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.03. Alumis had a negative net margin of 5,844.54% and a negative return on equity of 86.62%. The company had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $1.90 million. As a group, equities analysts forecast that Alumis Inc. will post -2.95 EPS for the current year.
Insiders Place Their Bets
In other news, Director Srinivas Akkaraju sold 96,131 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $10.55, for a total transaction of $1,014,182.05. Following the transaction, the director directly owned 2,025,493 shares of the company’s stock, valued at $21,368,951.15. This represents a 4.53% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 99,754 shares of company stock worth $1,037,804. 33.70% of the stock is currently owned by insiders.
Key Stories Impacting Alumis
Investors following ALMS have been watching these stories:
- Positive Sentiment: Alumis reported new Phase 3 data showing rapid, durable improvements in plaque psoriasis. The company said envudeucitinib had the highest publicly reported Week 48 PASI 100 response rate among existing and investigational oral psoriasis therapies, reinforcing its potential clinical differentiation. Alumis Q3 2026 financial results and business updates
- Neutral Sentiment: Q3 adjusted performance was slightly better than expected: the loss was $0.73 per share versus the $0.76 consensus, while revenue of $1.91 million was essentially in line with estimates of $1.90 million. The small beat is tempered by continued losses. Alumis earnings results
- Negative Sentiment: Wells Fargo cut its price target to $18 from $25, and HC Wainwright lowered its target to $9 from $15. Both firms kept bullish ratings—Overweight and Buy, respectively—but the reductions may signal more cautious expectations and pressure the stock. Wells Fargo price target report
Alumis Profile
Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.
Featured Articles
- Five stocks we like better than Alumis
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Want to see what other hedge funds are holding ALMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alumis Inc. (NASDAQ:ALMS – Free Report).
Receive News & Ratings for Alumis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alumis and related companies with MarketBeat.com's FREE daily email newsletter.
